Compositions and methods for inhibiting HMGB1 expression

This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of HMGB1 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of HMGB1 expression may also be designed to include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat liver fibrosis and related conditions..

Medienart:

Patent

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Europäisches Patentamt - (2020) vom: 16. Jan. Zur Gesamtaufnahme - year:2020

Sprache:

Englisch

Beteiligte Personen:

ABRAMS MARC [VerfasserIn]
CHOPDA GIRISH [VerfasserIn]
PARK JIHYE [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
bio
C07H: Sugars; derivatives thereof; nucleosides; nucleotid (...)
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2020-01-16, Last update posted on www.tib.eu: 2024-04-29, Last updated: 2024-05-03

Patentnummer:

AU2018294415

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA004206665